Orphan Drugs: Pharma/DTC genetic testing partnerships
The rapidly developing field of direct-to-consumer (DTC) genetic testing offers orphan drug developers the opportunity to directly support patients and HCPs while unlocking new insights in rare diseases that can inform clinical development programs. Partnership with genetic testing companies is key, but what are the pros, cons and dangers of operating in this unregulated space? In this report, experts in the field examine the value and benefits of a DTC testing strategy and explore the essential factors that make for partnering success.
Companies
Amgen, Novartis, GlaxoSmithKline, AstraZeneca, Takeda, Clovis Oncology, Invitae, PTC Therapeutics, J&J, Alnylam, 23andMe
- Subject synopsis
- Research methodology and objectives
- Key insights summary
- Issues and insights
- The role of genetic testing in orphan drug development
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Benefits and drawbacks of genetic testing for orphan drug development
- Issue summary
- Questions
- Key insights
- Supporting quotes
- DTC genetic testing for rare diseases
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Partnerships in genetic testing for rare diseases
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Evolution of DTC genetic testing for rare diseases
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Further Reading
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook